<DOC>
	<DOCNO>NCT02581657</DOCNO>
	<brief_summary>This study randomize , double-blind ( Investigator study subject ) , placebo control multiple dose sequential ascend dose study enroll 47 male female subject type 2 diabetes mellitus ( T2DM ) four cohort .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , PK PD Response PE0139 Injection Adult Subjects With T2DM</brief_title>
	<detailed_description>This study randomize , double-blind ( Investigator study subject ) , placebo control multiple dose sequential ascend dose study enroll 47 male female subject T2DM four cohort ; ( 6 active/2 placebo subject cohort 1 , 9 active/4 placebo subsequent cohort ) . This study evaluate safety , tolerability , pharmacokinetics pharmacodynamic response PE0139 presence exist stable non-insulin antidiabetic background therapy . Subjects return weekly total 6 dos study drug . Study remain active , recruit subject receive active study drug follow secondary outcome measure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Willing able sign write informed consent follow studyrelated procedure ; Male subject female subject childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study drug ; Body mass index ≥ 18 kg/m2 ≤ 45 kg/m2 ; Diagnosed T2DM HbA1c ≥ 7.5 % &lt; 11.0 % currently take noninsulin antidiabetic therapy stable dose ( ) 3 month prior screen ; Willing able comply study procedure include wear continuous glucose monitoring device performance frequent selfmonitored blood glucose profile accord protocol ; Minimum 7day average daily glucose 154 mg/dL ( base CGM ) baseline evaluation ; Willing refrain take acetaminophen ( paracetamol ) containing product ( e.g. , Tylenol® ) 24 hour prior placement CGM device throughout time period CGM device worn ; Live work area reliable Verizon cellular service transmission glucose data require use Telcare Glucose Monitoring System . Clinical diagnosis Type 1 diabetes ; Currently take routinely take , within 6 month prior screen , long shortacting insulin ; Selfreported significant change weight define either loss gain ≥ 10 % three month period prior screen screen randomization ; Known allergy , serious adverse effect cause approve , investigational insulin product component ; Currently take follow medication : thiazide furosemide diuretic , betablockers , estrogens hormonal replacement therapy , chronic medication know adverse effect glucose tolerance level unless subject stable dos agent least 2 month prior screen plan change concomitant medication usage study period ; Selfreported history severe hypoglycemia hypoglycemic unawareness , judge Investigator ; Selfreported history acute complication secondary diabetes within last 6 month prior screen sign symptom clinically significant diabetes related complication prior screen ; Malignant disease define : Selfreported history malignant melanoma breast cancer ; Selfreported history type cancer ( exclude basal/squamous cell carcinoma cervical carcinoma treat condition currently active ) within last 5 year prior screen ; Unstable cardiovascular disease define one following : Selfreported history stroke , transient ischemic attack , myocardial infarction within 6 month prior screen ; Selfreported history currently NYHA Class IIIIV heart failure prior screening ; Selfreported history unstable angina within 3 month prior screen ; Uncontrolled/sustained hypertension ; Selfreported history clinically significant ECG abnormality evidence clinically significant ECG abnormality ; Clinically significant renal and/or hepatic dysfunction note safety lab ; Absolute requirement corticosteroid routinely receive systemic steroid within 12 month prior randomization use inhale corticosteroid within 1 month prior randomization . A single short course treatment systemic steroid treat acute infection exclude subject take 3 month screen ; Pregnant lactate female subject ; Known history alcohol abuse use illicit drug within 1 year prior screening , and/or test positive alcohol illicit drug prior randomization . Note : A subject consider violation study test positive prior plan dose discontinue study ; Positive screen human immunodeficiency virus antibody , hepatitis B surface antigen , hepatitis C virus antibody screen ; Previously receive PE0139 ; Participating study receive investigational medication device within 30 day prior screen take part nonmedication study , opinion Investigator , would interfere outcome study ; Other medical psychiatric condition , opinion Investigator , would place subject increase risk would preclude obtain voluntary consent would confound secondary objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>